{"pmid":32448490,"title":"Mysterious Virus: A Review on Behavior and Treatment Approaches of the Novel Coronavirus, 2019-nCoV.","text":["Mysterious Virus: A Review on Behavior and Treatment Approaches of the Novel Coronavirus, 2019-nCoV.","At the end of the year 2019, the novel coronavirus (2019-nCoV) was spreading in Wuhan, China, and the outbreak process has a high speed. It was recognized as a pandemic by the World Health Organization (WHO) on 11 March 2020. Coronaviruses are enveloped and single-stranded RNA that have several families including Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). The pathogenesis mechanism and disease outcomes of SARS and MERS are now clear to some extent, but little information is available for 2019-nCoV. This newly identified corona virus infection represents flu-like symptoms, but usually the first symptoms are fever and dry cough. There has been no specific treatment against 2019-nCoV up to now, and physicians only apply supportive therapy. In the present article, we made an attempt to review the behavior of the virus around the world, epidemiology, a pathway for influx into the host cells, clinical presentation, as well as the treatments currently in use and future approaches; nitazoxanide may be our dream drug. We hope that this review has a positive impact on public knowledge for helping to deal with the 2019-nCoV and move one step forward toward its treatment in the near future.","Arch Med Res","Hemmati, Farshad","Saedi, Samira","Hemmati-Dinarvand, Mohsen","Zarei, Marzie","Seghatoleslam, Atefeh","32448490"],"abstract":["At the end of the year 2019, the novel coronavirus (2019-nCoV) was spreading in Wuhan, China, and the outbreak process has a high speed. It was recognized as a pandemic by the World Health Organization (WHO) on 11 March 2020. Coronaviruses are enveloped and single-stranded RNA that have several families including Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). The pathogenesis mechanism and disease outcomes of SARS and MERS are now clear to some extent, but little information is available for 2019-nCoV. This newly identified corona virus infection represents flu-like symptoms, but usually the first symptoms are fever and dry cough. There has been no specific treatment against 2019-nCoV up to now, and physicians only apply supportive therapy. In the present article, we made an attempt to review the behavior of the virus around the world, epidemiology, a pathway for influx into the host cells, clinical presentation, as well as the treatments currently in use and future approaches; nitazoxanide may be our dream drug. We hope that this review has a positive impact on public knowledge for helping to deal with the 2019-nCoV and move one step forward toward its treatment in the near future."],"journal":"Arch Med Res","authors":["Hemmati, Farshad","Saedi, Samira","Hemmati-Dinarvand, Mohsen","Zarei, Marzie","Seghatoleslam, Atefeh"],"date":"2020-05-26T11:00:00Z","year":2020,"_id":"32448490","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.arcmed.2020.04.022","keywords":["2019-ncov","infection","novel coronavirus","respiratory problem","treatment approach"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["nitazoxanide"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667785213914120193,"score":9.490897,"similar":[{"pmid":32226290,"pmcid":"PMC7098027","title":"Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19.","text":["Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19.","Coronaviruses (CoVs) are a group of enveloped, single-stranded positive genomic RNA viruses and some of them are known to cause severe respiratory diseases in human, including Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS) and the ongoing coronavirus disease-19 (COVID-19). One key element in viral infection is the process of viral entry into the host cells. In the last two decades, there is increasing understanding on the importance of the endocytic pathway and the autophagy process in viral entry and replication. As a result, the endocytic pathway including endosome and lysosome has become important targets for development of therapeutic strategies in combating diseases caused by CoVs. In this mini-review, we will focus on the importance of the endocytic pathway as well as the autophagy process in viral infection of several pathogenic CoVs inclusive of SARS-CoV, MERS-CoV and the new CoV named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and discuss the development of therapeutic agents by targeting these processes. Such knowledge will provide important clues for control of the ongoing epidemic of SARS-CoV-2 infection and treatment of COVID-19.","Int J Biol Sci","Yang, Naidi","Shen, Han-Ming","32226290"],"abstract":["Coronaviruses (CoVs) are a group of enveloped, single-stranded positive genomic RNA viruses and some of them are known to cause severe respiratory diseases in human, including Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS) and the ongoing coronavirus disease-19 (COVID-19). One key element in viral infection is the process of viral entry into the host cells. In the last two decades, there is increasing understanding on the importance of the endocytic pathway and the autophagy process in viral entry and replication. As a result, the endocytic pathway including endosome and lysosome has become important targets for development of therapeutic strategies in combating diseases caused by CoVs. In this mini-review, we will focus on the importance of the endocytic pathway as well as the autophagy process in viral infection of several pathogenic CoVs inclusive of SARS-CoV, MERS-CoV and the new CoV named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and discuss the development of therapeutic agents by targeting these processes. Such knowledge will provide important clues for control of the ongoing epidemic of SARS-CoV-2 infection and treatment of COVID-19."],"journal":"Int J Biol Sci","authors":["Yang, Naidi","Shen, Han-Ming"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32226290","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.7150/ijbs.45498","keywords":["covid-19","coronaviruses","sars-cov-2","autophagy","endocytic pathway"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138492439101440,"score":192.20395},{"pmid":32412679,"title":"Novel Coronavirus disease 2019 (COVID-19) and neurodegenerative disorders.","text":["Novel Coronavirus disease 2019 (COVID-19) and neurodegenerative disorders.","During the last few months, the whole humanity is experiencing largest and most severe sudden influx of COVID-19 outbreak caused by the novel Coronavirus (CoV) originated from Wuhan, China. According to the WHO reports, total 3862676 positive cases and 265961 deaths have been recorded worldwide due to COVID-19 infection as of 09 May 2020. CoVs are a large family of viruses (enveloped, single-stranded RNA viruses), which includes Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome-related Coronavirus (MERS-CoV). New SARS CoV2 is the members of Betacoronavirus genus. These viruses cause infections in bats, camels and humans, and a few other associated species. Despite many neurologic complications associated with SARSCoV-2 infection, it is still unclear whether these symptoms results from direct neural injury or due to some other reason. Currently, it appears that most of the neurological symptoms of COVID-19 are non-specific and secondary to the systemic illness. A single case of acute hemorrhagic necrotizing encephalopathy has been reported. SARS-CoV-2 associated Guillain-Barre syndrome is an atypical case. Till today, no convincing evidence is available to confirm that the SARS-CoV-2 virus directly affects nerves system in humans. However, post-infection surveillance will be necessary to identify the possible post-COVID-19 neurologic syndromes. This article is protected by copyright. All rights reserved.","Dermatol Ther","Singh, Anurag Kumar","Bhushan, Bharat","Maurya, Anand","Mishra, Gaurav","Singh, Santosh Kumar","Awasthi, Rajendra","32412679"],"abstract":["During the last few months, the whole humanity is experiencing largest and most severe sudden influx of COVID-19 outbreak caused by the novel Coronavirus (CoV) originated from Wuhan, China. According to the WHO reports, total 3862676 positive cases and 265961 deaths have been recorded worldwide due to COVID-19 infection as of 09 May 2020. CoVs are a large family of viruses (enveloped, single-stranded RNA viruses), which includes Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome-related Coronavirus (MERS-CoV). New SARS CoV2 is the members of Betacoronavirus genus. These viruses cause infections in bats, camels and humans, and a few other associated species. Despite many neurologic complications associated with SARSCoV-2 infection, it is still unclear whether these symptoms results from direct neural injury or due to some other reason. Currently, it appears that most of the neurological symptoms of COVID-19 are non-specific and secondary to the systemic illness. A single case of acute hemorrhagic necrotizing encephalopathy has been reported. SARS-CoV-2 associated Guillain-Barre syndrome is an atypical case. Till today, no convincing evidence is available to confirm that the SARS-CoV-2 virus directly affects nerves system in humans. However, post-infection surveillance will be necessary to identify the possible post-COVID-19 neurologic syndromes. This article is protected by copyright. All rights reserved."],"journal":"Dermatol Ther","authors":["Singh, Anurag Kumar","Bhushan, Bharat","Maurya, Anand","Mishra, Gaurav","Singh, Santosh Kumar","Awasthi, Rajendra"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32412679","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/dth.13591","keywords":["covid-19","coronavirus","neurodegenerative disorders","viral outbreak"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism"],"weight":1,"_version_":1666989866113564672,"score":175.74008},{"pmid":32325767,"title":"COVID-19 Drug Discovery Using Intensive Approaches.","text":["COVID-19 Drug Discovery Using Intensive Approaches.","Since the infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in China during December 2019, the coronavirus disease 2019 (COVID-19) has spread on a global scale, causing the World Health Organization (WHO) to issue a warning. While novel vaccines and drugs that target SARS-CoV-2 are under development, this review provides information on therapeutics which are under clinical trials or are proposed to antagonize SARS-CoV-2. Based on the information gained from the responses to other RNA coronaviruses, including the strains that cause severe acute respiratory syndrome (SARS)-coronaviruses and Middle East respiratory syndrome (MERS), drug repurposing might be a viable strategy. Since several antiviral therapies can inhibit viral replication cycles or relieve symptoms, mechanisms unique to RNA viruses will be important for the clinical development of antivirals against SARS-CoV-2. Given that several currently marketed drugs may be efficient therapeutic agents for severe COVID-19 cases, they may be beneficial for future viral pandemics and other infections caused by RNA viruses when standard treatments are unavailable.","Int J Mol Sci","Asai, Ayumu","Konno, Masamitsu","Ozaki, Miyuki","Otsuka, Chihiro","Vecchione, Andrea","Arai, Takahiro","Kitagawa, Toru","Ofusa, Ken","Yabumoto, Masami","Hirotsu, Takaaki","Taniguchi, Masateru","Eguchi, Hidetoshi","Doki, Yuichiro","Ishii, Hideshi","32325767"],"abstract":["Since the infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in China during December 2019, the coronavirus disease 2019 (COVID-19) has spread on a global scale, causing the World Health Organization (WHO) to issue a warning. While novel vaccines and drugs that target SARS-CoV-2 are under development, this review provides information on therapeutics which are under clinical trials or are proposed to antagonize SARS-CoV-2. Based on the information gained from the responses to other RNA coronaviruses, including the strains that cause severe acute respiratory syndrome (SARS)-coronaviruses and Middle East respiratory syndrome (MERS), drug repurposing might be a viable strategy. Since several antiviral therapies can inhibit viral replication cycles or relieve symptoms, mechanisms unique to RNA viruses will be important for the clinical development of antivirals against SARS-CoV-2. Given that several currently marketed drugs may be efficient therapeutic agents for severe COVID-19 cases, they may be beneficial for future viral pandemics and other infections caused by RNA viruses when standard treatments are unavailable."],"journal":"Int J Mol Sci","authors":["Asai, Ayumu","Konno, Masamitsu","Ozaki, Miyuki","Otsuka, Chihiro","Vecchione, Andrea","Arai, Takahiro","Kitagawa, Toru","Ofusa, Ken","Yabumoto, Masami","Hirotsu, Takaaki","Taniguchi, Masateru","Eguchi, Hidetoshi","Doki, Yuichiro","Ishii, Hideshi"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32325767","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.3390/ijms21082839","keywords":["covid-19","coronavirus","drug discovery","drug repositioning","infection"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666138494548836352,"score":165.67915},{"pmid":32419926,"pmcid":"PMC7202090","title":"Use of the informational spectrum methodology for rapid biological analysis of the novel coronavirus 2019-nCoV: prediction of potential receptor, natural reservoir, tropism and therapeutic/vaccine target.","text":["Use of the informational spectrum methodology for rapid biological analysis of the novel coronavirus 2019-nCoV: prediction of potential receptor, natural reservoir, tropism and therapeutic/vaccine target.","A novel coronavirus recently identified in Wuhan, China (SARS-CoV-2) has expanded the number of highly pathogenic coronaviruses affecting humans. The SARS-CoV-2 represents a potential epidemic or pandemic threat, which requires a quick response for preparedness against this infection. The present report uses the informational spectrum methodology to identify the possible origin and natural host of the new virus, as well as putative therapeutic and vaccine targets. The performed in silico analysis indicates that the newly emerging SARS-CoV-2 is closely related to severe acute respiratory syndrome (SARS)-CoV and, to a lesser degree, Middle East respiratory syndrome (MERS)-CoV. Moreover, the well-known SARS-CoV receptor (ACE2) might be a putative receptor for the novel virus as well. Actin protein was also suggested as a host factor that participates in cell entry and pathogenesis of SARS-CoV-2; therefore, drugs modulating biological activity of this protein (e.g. ibuprofen) were suggested as potential candidates for treatment of this viral infection. Additional results indicated that civets and poultry are potential candidates for the natural reservoir of the SARS-CoV-2, and that domain 288-330 of S1 protein from the SARS-CoV-2 represents promising therapeutic and/or vaccine target.","F1000Res","Veljkovic, Veljko","Vergara-Alert, Julia","Segales, Joaquim","Paessler, Slobodan","32419926"],"abstract":["A novel coronavirus recently identified in Wuhan, China (SARS-CoV-2) has expanded the number of highly pathogenic coronaviruses affecting humans. The SARS-CoV-2 represents a potential epidemic or pandemic threat, which requires a quick response for preparedness against this infection. The present report uses the informational spectrum methodology to identify the possible origin and natural host of the new virus, as well as putative therapeutic and vaccine targets. The performed in silico analysis indicates that the newly emerging SARS-CoV-2 is closely related to severe acute respiratory syndrome (SARS)-CoV and, to a lesser degree, Middle East respiratory syndrome (MERS)-CoV. Moreover, the well-known SARS-CoV receptor (ACE2) might be a putative receptor for the novel virus as well. Actin protein was also suggested as a host factor that participates in cell entry and pathogenesis of SARS-CoV-2; therefore, drugs modulating biological activity of this protein (e.g. ibuprofen) were suggested as potential candidates for treatment of this viral infection. Additional results indicated that civets and poultry are potential candidates for the natural reservoir of the SARS-CoV-2, and that domain 288-330 of S1 protein from the SARS-CoV-2 represents promising therapeutic and/or vaccine target."],"journal":"F1000Res","authors":["Veljkovic, Veljko","Vergara-Alert, Julia","Segales, Joaquim","Paessler, Slobodan"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32419926","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.12688/f1000research.22149.3","keywords":["2019-ncov","mers","sars","wuhan coronavirus"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667342288181788673,"score":164.58842},{"pmid":32093211,"pmcid":"PMC7074453","title":"Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China.","text":["Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China.","In December 2019, cases of unidentified pneumonia with a history of exposure in the Huanan Seafood Market were reported in Wuhan, Hubei Province. A novel coronavirus, SARS-CoV-2, was identified to be accountable for this disease. Human-to-human transmission is confirmed, and this disease (named COVID-19 by World Health Organization (WHO)) spread rapidly around the country and the world. As of 18 February 2020, the number of confirmed cases had reached 75,199 with 2009 fatalities. The COVID-19 resulted in a much lower case-fatality rate (about 2.67%) among the confirmed cases, compared with Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). Among the symptom composition of the 45 fatality cases collected from the released official reports, the top four are fever, cough, short of breath, and chest tightness/pain. The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis. The source of the virus and the pathogenesis of this disease are still unconfirmed. No specific therapeutic drug has been found. The Chinese Government has initiated a level-1 public health response to prevent the spread of the disease. Meanwhile, it is also crucial to speed up the development of vaccines and drugs for treatment, which will enable us to defeat COVID-19 as soon as possible.","J Clin Med","Deng, Sheng-Qun","Peng, Hong-Juan","32093211"],"abstract":["In December 2019, cases of unidentified pneumonia with a history of exposure in the Huanan Seafood Market were reported in Wuhan, Hubei Province. A novel coronavirus, SARS-CoV-2, was identified to be accountable for this disease. Human-to-human transmission is confirmed, and this disease (named COVID-19 by World Health Organization (WHO)) spread rapidly around the country and the world. As of 18 February 2020, the number of confirmed cases had reached 75,199 with 2009 fatalities. The COVID-19 resulted in a much lower case-fatality rate (about 2.67%) among the confirmed cases, compared with Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). Among the symptom composition of the 45 fatality cases collected from the released official reports, the top four are fever, cough, short of breath, and chest tightness/pain. The major comorbidities of the fatality cases include hypertension, diabetes, coronary heart disease, cerebral infarction, and chronic bronchitis. The source of the virus and the pathogenesis of this disease are still unconfirmed. No specific therapeutic drug has been found. The Chinese Government has initiated a level-1 public health response to prevent the spread of the disease. Meanwhile, it is also crucial to speed up the development of vaccines and drugs for treatment, which will enable us to defeat COVID-19 as soon as possible."],"journal":"J Clin Med","authors":["Deng, Sheng-Qun","Peng, Hong-Juan"],"date":"2020-02-26T11:00:00Z","year":2020,"_id":"32093211","source":"PubMed","week":"20209|Feb 24 - Mar 01","doi":"10.3390/jcm9020575","keywords":["2019-ncov","covid-19","sars-cov-2","clinical characteristics","coronavirus","diagnosis","pneumonia","prevention and control","public health","treatment"],"locations":["Wuhan","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Prevention","Mechanism","Diagnosis"],"weight":1,"_version_":1666138490806468608,"score":163.03374}]}